Akums Drugs and Pharmaceuticals Limited — Updates, 08-08-2025: Press Release

Akums posted strong Q1 FY26 results: Total income ₹1,051 Cr, Adj EBITDA ₹156 Cr (up 19.1% YoY). Margins improved to 14.8%. Achieved 1,000 DCGI approvals (27 in Q1) and secured a patent for a key formulation. Internationally, secured first EU dossier approval (Rivaroxaban) and filed a Dapagliflozin combination dossier in Switzerland. EU commercial supplies start April 2027. Received €100 million for EU contract, boosting cash surplus to ₹1,518 Cr for strategic growth.